IGF1R is one of the phosphorylated receptor tyrosine kinases present in AML cases, and it has been linked to mutant RAS-positive AML, having the potential therapeutic benefits of dual suppression of IGF1R and RAS signaling [44]. The gene discussed is IGF1R; the disease is acute myeloid leukemia.